• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Crinetics Pharmaceuticals, Inc. - Common Stock (NQ: CRNX )

    53.60 +0.86 (+1.63%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Crinetics Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
    Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation. 
    Via Benzinga
    Exposures Product Safety
    Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 12, 2024
    Via Benzinga
    What Analysts Are Saying About Crinetics Pharmaceuticals Stock
    Via Benzinga
    A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
    Via Benzinga
    Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
    Via Benzinga
    Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
    FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
    CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
    ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-Care 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    7 Biotech Stocks to Boost Your Portfolio to Peak Health
    With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
    Via InvestorPlace
    EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
    Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives 
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.